INTRODUCTION
============

Craniosynostosis (CS) is the premature fusion of one or more cranial sutures and may be syndromic or nonsyndromic.^[@R1]^ CS occurs one in every 2,000--2,500 live births.^[@R2]^ The gold standard for diagnosis is a 3D-CT scan.^[@R3]^ Sagittal CS is the premature fusion of the sagittal cranial suture, resulting in a lengthened cranium in the anterior--posterior direction with stunted growth in the parietal and temporal regions.^[@R4],[@R5]^ Patients with Isolated Sagittal Synostosis (ISS) have no other sutural involvement, and account for half of all cases of CS.^[@R6],[@R7]^ Reports of systemic associations in patients with ISS are sparse.^[@R8]--[@R16]^ This study investigates the incidence of systemic disease and syndromic diagnosis in a cohort of patients presenting with ISS. Our investigation was inclusive of previously identified (such as Rickets and Noonan syndrome), as well as previously unidentified or underreported (such as seizures, Stickler and Waardenburg) syndromes and systemic findings in patients with ISS.

METHODS
=======

Patients diagnosed with ISS were identified through perusal of clinical databases (pediatric ophthalmology, radiology, neurosurgery, and cleft craniofacial departments) for the years 2007--2017 at a single institution. Our children's hospital is a major referral center for craniofacial anomalies. All patients included in the study obtained a CT diagnosis of CS. Each patient was then evaluated by the cleft-craniofacial team. Only patients with isolated sagittal fusion---meaning, patients with sagittal synostosis and no other sutural involvement---were included. Patients who developed ISS after a shunting procedure for hydrocephalus or had multisutural CS were excluded. Patients were then divided according to their age at diagnosis of ISS. Group A: early onset (cases diagnosed at ≤ 1 year of age), Group B: late onset (cases diagnosed after 1 year of age). Patient notes were examined for the following data sets: date of birth, age of presentation, age at last follow-up, other congenital anomalies, systemic conditions, syndromic diagnosis, and molecular testing results. The genetic testing protocol at our institution includes SNP, exome, and specific panel testing. Exome testing can be employed as first; second; or third tier testing. First tier testing also includes SNP arrays (combo chip for complete micro arrays with SNP arrays) to determine copy number and copy neutral variation. If phenotype is very clear then a panel is recommended (eg, Noonan or CTD like Loeys-Dietz). Different services at our institution simultaneously phenotype during consultations and management; which includes imaging and biochemical testing. Finally, clinical testing for genetics may be determined by the family history. Statement of IRB approval:IRB\#:REN17110211/PRO16110394.

All systemic diagnoses were initially included. Once all were gathered, nonspecific findings or those that were not causative or etiologically related were excluded, such as cerebral palsy, Gastroesophageal reflux disease, Moyamoya disease, caudal regression, G6PD deficiency, congenital nonstationary night blindness, Gaucher, and VACTERL syndromes. Patient information regarding genetic diagnoses was verified by a genetic counselor. IRB approval was obtained before the beginning of this research project. Statistics were conducted using SPSS, and a chi-square test was run to determine a significant difference in the incidence of systemic involvement between Group A and B. None of the authors has a financial interest in any of the products, devices, or drugs mentioned in this article.

RESULTS
=======

Three hundred seventy-seven patients with ISS were identified. Systemic conditions were identified in 188/377 of the total cohort. Thirty-eight percent of early onset patients had systemic involvement, and 60% of late onset patients had systemic involvement. Within the 188 patients with systemic involvement, 48 (25%) had an identifiable syndrome. Of these 48, 42 underwent molecular testing. In total, 38/48 syndromes were confirmed via genetic testing (79%). The complete range of syndromic and molecular diagnoses is shown in Table [1](#T1){ref-type="table"}.

###### 

Syndromes and Chromosomal Abnormalities in Total ISS Cohort

  Type                                                                                                                      Sex (M/F)   Genetic Testing Results
  ---------------------------------------------- -------------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Neuro/neurocutaneous: total: 2                 Linear nevus sebaceous syndrome: 1 total                                   F           No testing
                                                 Acrocallosal syndrome: 1 total                                             F           KIF7: c.2364delC (p.Arg789fs) and c.2593-3C\>G
  RASopathies: total: 8                          Cardiofaciocutaneous syndrome: 2 total                                     F           BRAF: c.1741A\>G (p.Asn581Asp)
                                                                                                                            M           BRAF: c.1497A\>C(p.K499N)
                                                 Noonan syndrome: 6 total                                                   M           KRAS: c.40G\>A (pg.Val14Ile)
                                                                                                                            M           PTPN 11: c.188A\>G, (p.Tyr63Cys)
                                                                                                                            M           BRAF: c.735A\>T (p.Leu245Phe)
                                                                                                                            F           Negative results
                                                                                                                            F           Negative results
                                                                                                                            M           c.1096dup(p.T367fs) mutation in the FANCL gene
  Metabolic disorders: 3                         Autosomal recessive rickets: 1 total                                       F           DMP1: c.403C\>T (p.Gly135Term); DMP1 8.15 kb deletion
                                                 X-linked rickets: 2 total                                                  M           X-linked rickets
                                                                                                                            M           X-linked rickets
  Connective tissue disorders: total: 4          Loeys-Dietz syndrome: 1 total                                              M           TGFBR1: c.997G\>T; (p.ASp333Tyr)
                                                 Type II Stickler syndrome: 1 total                                         M           COLIIA1: IVS37 + 5G\>A
                                                 Multiple exotoses Type I: 1 total                                          M           Confirmed EXT1 mutation, maternally inherited
                                                 Williams syndrome: 1 total                                                 F           No testing
  Craniofacial disorders: total: 3               Pfeiffer syndrome: 1 total                                                 M           No testing
                                                 Craniofrontonasal dysplasia: 1 total                                       M           EFNB1: c.466C\>T (p.Arg156Cys)
                                                 Saethre-Chozten suspect: 1 total                                           F           Negative results
  Single gene mutations: total: 4                KCNT1 mutation; mitochondrial disorder, (complex IV deficiency): 1 total   F           KCNT1: c.2683T\>C, (p.Tyr895His)
                                                 FLNB and ADAMTS10 mutations: 1 total                                       F           FLNB: c.735_736dupGG (p.A246fs); ADAMTS10: c.1265C\>T(p.A422V)
                                                 MESP2 mutation: 1 total                                                    M           MESP2: a c.813-814del mutation
                                                 Connexin 26 (GJB2): 1 total                                                M           Connexin 26 (GJB2): c.35delG, 167delT
  Skeletal disorders: total: 2                   Osteogenesis imperfecta type V: 1 total                                    M           No testing
                                                 Gorham syndrome: 1 total                                                   M           Negative results
  Pigmentary disorders: total: 1                 Waardenburg syndrome: 1 total                                              M           PAX3: p.R26X
  Chromosome (micro array) syndromes: total: 4   DiGeorge syndrome: 1 total                                                 M           22q11.2 deletion
                                                 Turner syndrome: 1 total                                                   F           45X
                                                 Kleefestra syndrome: 1 total                                               M           9q34.3 deletion: 279.6Kb deletion including EHMT1
                                                 Cohen syndrome (suspect): 1 total                                          M           2q14.3 deletion and 16p13.3 deletion of 158 kb. Contains part of the RBFOX1(A2BP1) gene
  Other Total: 2                                 Ectodermal dysplasia: 1 total                                              M           Negative results
                                                 Heterotaxy syndrome: 1 total                                               M           NODAL: c.904C\>T
  Chromosomal abnormalities: total: 15           Chromosomal translocation syndrome of 5q and 7q: 1 total                   F           Chromosomal translocation of 5q and 7q
                                                 12q21 deletion: 1 total                                                    M           12q21 deletion: with interstitial deletion of chromosome 12. Breakpoints at bands 12q21.2 and 12q22. This results in partial monosomy for 12q-\>12q22
                                                 Ring chromosome 8: 2 total                                                 M           Deletion of 11.99 Mb of DNA from 18p11.21pter and 448.2 kb of DNA from 18q23qter; duplication of genetic material from 18q23q23; duplication of 1.44 Mb of DNA from 6p25.1p24.3.
                                                                                                                            F           8p12q11.21 deletion: 18 Mb and containing 52 genes; mosaicism for a variable number of ring 8 chromosomes.
                                                 16p micro array aberration(s) 5 total                                      M           16p.13.3 deletion: includes part of the RBFOX1 (A2BP1) gene
                                                                                                                            M           16p13.2 deletion: including the USP7 gene
                                                                                                                            M           16p13.12p13.11. duplication
                                                                                                                            M           16p13.11 deletion: Region contains the PDXC1 and NTAN1 genes
                                                                                                                            M           16p13.3 deletion region and duplication of 15q24.2q26.3
                                                 Partial trisomy 3q/monosomy 18p: 1 total                                   M           46,XY, der(18)t(3;18). Effectively, this is a partial Trisomy 3q and partial monosomy 18p
                                                 15q13.3. deletion: 1 Total                                                 M           15q13.3 microdeletion syndrome. Deletion involves SZT2: c.5235_5236del(p.H1745fs)
                                                 Chromosome 2 deletion: 1 total                                             M           3.5 MB deletion of chromosome 2
                                                 1q21.1 deletion: 1 total                                                   M           Deletion on chromosome 1q21.1 that spans at least 384 Kb.
                                                 1p36.12 duplication: 1 total                                               M           Duplication at 1p36.12 of unknown significance
                                                 Chromosome 2 deletion, 15q duplication: 1 total                            F           Unknown

In the total cohort, 140/377 patients (37%) did not have a syndromic diagnosis but had systemic involvement in one or more organ systems. When statistically analyzed by age of presentation (early/group A or late/group B), the incidence of systemic involvement was significantly higher in the late onset group: 38% in Group A versus 60% in Group B (*P* \< 0.001). Of the 188 patients with systemic and or syndromic diagnoses, 134/188 had central nervous system anomalies (71%). Looking specifically at these 134 patients, 4% had tethered cord, 11% had hydrocephalus or raised intracranial pressure, 28% had seizures/epilepsy, and 37% had developmental delay. If we look at the entire cohort of ISS patients (n = 377), 4% had raised intracranial pressure or hydrocephalus, 10% had seizures, and 13% had developmental delay. Sixty-one of 377 (16%) patients were diagnosed with other craniofacial anomalies, including cleft palate (9%), torticollis (2%), macrocephaly (4%), microcephaly (1%), and Pierre Robin sequence (1%).

Limb anomalies were identified in 7 patients (1.8%). Urogenital abnormalities were identified in 10 patients (2.6%). We identified 8 patients with a diagnosis of ISS and a clinical diagnosis of RASopathy (Table [2](#T2){ref-type="table"}): 6 diagnosed with Noonan syndrome and 2 with cardiofaciocutaneous syndrome (CFC). Five of these patients had molecular confirmation (3 Noonan 2 CFC). We describe 3 patients with metabolic disorders (Table [2](#T2){ref-type="table"}), 2 of whom had Rickets. Four patients tested positive for single-gene mutations. Fifteen patients with chromosomal abnormalities were identified (Table [1](#T1){ref-type="table"}). Three of the 15 (20%) patients identified with chromosomal abnormalities had chromosomal aberrations previously reported in patients with CS. Twenty of 377 patients (5%) with autism spectrum disorder (ASD): 16 with Autism, and 4 with Asperger's.

###### 

Systemic Findings

  Systemic Finding                        Includes                                                                                                          Total Affected
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------- ----------------
  Seizures                                Febrile and afebrile                                                                                              38 (10%)
  Cardiac abnormalities                   ASD, VSD, PFO, PDA, murmur, arteriovenous malformation, aortic stenosis, trileaflet valve, coarctation of aorta   31 (8%)
  Renal/urogenital abnormalities          Renal aplasia, horshoe kidney cryptorchidism, hypospadias                                                         19 (5%)
  Structural neurological abnormalities   Tethered cord, hydrocephalus                                                                                      20 (5%)
  Developmental delay                     Speech, global, cognitive                                                                                         50 (13%)
  Autism spectrum disorder                Autism, aspergers                                                                                                 20 (5%)
  Cleft palate                            Submucous cleft palate                                                                                            35 (9%)
  Constitutional                          Micro/macrocephaly, Pierre Robin sequence, failure to thrive, short stature                                       35 (9%)
  Musculoskeletal/limb abnormalities      Polydactyly, syndactyly, torticollis, clubfeet                                                                    15 (4%)

DISCUSSION
==========

Single case reports and/or small case series^[@R10],[@R11],[@R15],[@R17]--[@R21]^ have reported associations between ISS and the syndromes listed in Table [3](#T3){ref-type="table"}. Specifically, our cohort contained Turner syndrome (n = 1), craniofrontonasal dysplasia (n = 1), rickets (n = 3), RASopathy (Noonan and CFC syndromes), (n = 8), osteogenesis imperfecta (n = 1), ectodermal dysplasia (n = 1), and Loeyz-Dietz (n = 1). We did not identify patients diagnosed with several of the syndromes previously reported in association with ISS (Table [3](#T3){ref-type="table"}). However, we describe ISS in association with conditions *not* previously described in the literature (Table [3](#T3){ref-type="table"}), including stickler syndrome (n = 1).

###### 

Syndromes Associated with ISS, Previously Reported, and Unreported

  Previously Reported Syndromes Appearing in Patients with ISS   Previously Unreported Syndromes Found in Our ISS Cohort   
  -------------------------------------------------------------- --------------------------------------------------------- ---------------------------------
  Turner syndrome                                                Crouzon's syndrome                                        Stickler syndrome
  Craniofrontonasal dysplasia                                    Frank-ter Haar syndrome                                   Kleefestra
  Rickets                                                        Ellis-van Creveld syndrome                                Waardenburg
  Noonan                                                         Sensenbrenner                                             Cohen syndrome
  Osteogenesis imperfecta                                        Pfeiffer-type Cardiocranial syndrome                      Acrocallosal syndrome
  Ectodermal dysplasia                                           Carpenter syndrome                                        Linear Sebaceous Nevus syndrome
  Turner syndrome                                                                                                          Pfeiffer syndrome
  Loeys-Dietz syndrome                                                                                                     DiGeorge syndrome
  Cardiofaciocutaneous syndrome                                                                                            

ISS is seldom included as a presenting feature of single gene CS syndromes---like Apert and Crouzon---but has been linked to chromosomal aberrations.^[@R22]^ However, we identified 3 patients diagnosed with ISS and craniofacial syndromes: Pfeiffer (n = 1), Craniofrontonasal Dysplasia (n = 1), and Saethre-Chotzen (n = 1).

Sagittal synostosis and RASopathy, particularly Noonan syndrome, have been reported together previously, in association with the following genes: *SHOC-2*, *KRAS*, *BRAF*, and *PTPN*.^[@R18],[@R23]--[@R25]^ CFC has also been previously reported in patients with ISS.^[@R24]^ Both of our patients diagnosed with CFC had mutations in BRAF. Three of 6 patients in our cohort who were clinically diagnosed with Noonan syndrome had mutations in *KRAS*, *BRAF*, and *PTPN* respectively, the 3 remaining patients did not reveal any mutations, but the panel used did not analyze *SHOC-2*. We recommend that patients with a Noonan-like phenotype undergo a RASopathy panel, inclusive of the *SHOC-2* gene and or whole exome sequencing.

Rickets has been described in association with CS previously.^[@R20],[@R21]^ We identified a single patient with ectodermal dysplasia, which has previously been reported with ISS.^[@R13]^ Given that more than half of patients reported in Lin's study diagnosed with ectodermal dysplasia also had ISS, there is likely a causative relationship, though the exact nature is unclear.

Single Gene Mutations
---------------------

Of the patients with single gene mutations, 1 presented with epilepsy, Chiari I malformation, plagiocephaly, and microcephaly. A syndromic diagnosis was not made, but he tested positive for a *KCNT1* mutation, which is associated with epilepsy. Another patient was found to have a mutation in the *MESP2* gene, which has been implicated in spondylocostal dysostosis type 2. Our patient did not have the typical phenotype of this condition, so it may be that we are seeing a milder/different end of the spectrum of phenotype caused by the *MESP2* mutation. We also identified a single patient with an *FLNB* mutation. Though they were not found in our patient, mutations in the *FLNB* gene may cause severe bone dysplasias.^[@R28]^ Missense mutations in this gene are also associated with Larsen syndrome and Boomerang Dysplasia, a lethal form of osteochondrodysplasia.^[@R29],[@R30]^

Chromosomal Abnormalities
-------------------------

Three of the 15 (20%) patients identified with chromosomal abnormalities had chromosomal aberrations previously reported in patients with CS: Kleefestra,^[@R30]^ 45,X (Turner syndrome)^[@R20]^ and 22q deletion (DiGeorge Syndrome),^[@R32],[@R33]^ of which only 45,X has been reported in a patient with ISS (6%). We identified several noteworthy anomalies which so far have not been described in patients with only ISS, such as a 1p36.12 duplication, which to date is of unknown significance. However, *deletions* of the same region of chromosome 1p36 constitute a deletion syndrome. It is associated with developmental delay, short stature, prominent forehead, congenital heart disease, hypotonia, and early death.^[@R34],[@R35]^ Another patient had a 1q21.1 deletion, which is also associated with developmental delay, schizophrenia, microcephaly, cardiac abnormalities, and cataracts.^[@R35]--[@R37]^ Another patient presented with a de novo microdeletion in 16p13.1, spanning the *NTAN* and *NDE1 genes*. Developmental delay, epilepsy, short stature, dysmorphic appearance, and behavioral problems are known to accompany this mutation. This disease has been clinically and molecularly diagnosed in fewer than 15 patients worldwide.^[@R38]^ We also identified 2 patients with 16p13.2 deletions.^[@R39],[@R40]^ One case report describes a patient with 16p13.2 and Pfeiffer syndrome *without* a diagnosis of CS.^[@R16]^ We have identified a patient with the same mutation, diagnosed with ISS, but not Pfeiffer syndrome. In total, our cohort contains 5 patients with 16p aberration(s) on microarrays. The fact that only 6% of the chromosomal aberrations described in our study have been previously reported in patients with ISS supports increased karyotyping and utilization of molecular cytogenetics in patients diagnosed with ISS who have systemic involvement.

Systemic Findings
-----------------

In our cohort, 38/377 (10%) ISS patients had seizures. Eighteen percent of these seizure were febrile. The association between CS and seizures has been previously described.^[@R26],[@R27]^ However---to the best of our knowledge---this is the first report suggesting that 1/10 patients with ISS will suffer from seizure activity. Our cohort contains 20 patients with ASD: 16 with Autism, and 4 with Asperger's. ASD has previously been described in patients with CS, and may be due to genetic, epigenetic, and environmental factors.^[@R42]^ Autism is associated with both sporadic mutations and syndromes like Fragile X and 22q11.2 deletion syndrome.^[@R42]--[@R44]^ Of the 20 patients identified with ASD, 4 had an additional syndromic diagnosis: CFC, 15q13.3.deletion, 16p.13.3 deletion, and congenital stationary night blindness.

In our cohort, the incidence of developmental delay was 13%. The association between developmental delay and CS is noted in many publications, and the incidence of neurocognitive deficits in patients with sagittal synostosis has been reported to be 3--5 times that of the unaffected population.^[@R45]--[@R52]^ Developmental delay in patients with single suture CS (SSC) has been described in studies and case reports,^[@R2],[@R11],[@R18],[@R31],[@R51]--[@R54]^ but there have been few studies of developmental delay in patients with ISS.^[@R46],[@R47],[@R49],[@R54]^ Additionally, a control-matched study of 209 patients with SSC reported that 3-year-olds with SSC scored lower on the Griffiths mental development scales than the control cohort who did not have a diagnosis of CS.^[@R54]^ A study of operated ISS patients revealed patients with ISS and developmental delay who underwent surgical repair demonstrated a reduction in their developmental delay as evidenced by performance on the Griffiths scale.^[@R54]^ But this is controversial.^[@R50]^ In the ISS population, developmental delay in language and speech are frequently reported.^[@R47],[@R52]^ In our cohort, 16 of the 50 patients diagnosed with developmental delay were also diagnosed with speech delay. Abnormal speech and language development have been reported in 1/1.7 of patients with nonsyndromic SSC, and as high as 37% in metopic-sagittal synostosis patients.^[@R52]^ Visual deficits have also been reported. Abnormalities in fixation shift have been reported in patients with ISS. One study inclusive of 15 patients with sagittal synostosis, reports 11/15 patients (73%) with ISS demonstrated abnormal fixation shift.^[@R55]^ Like developmental delay, visual function has been shown to improve postoperatively in patients with CS. In particular, patients with sagittal CS demonstrated a deficit in gross locomotor function which resolved after surgical correction of deformity.^[@R54]^ We recommend patients with ISS undergo full pediatric and ophthalmic evaluations in addition to their craniofacial assessment, considering that surgical intervention has been shown to ameliorate visual, cognitive, or developmental delays.^[@R54]^

To the best of our knowledge, this is the largest series investigating the incidence of syndromes/systemic involvement in patients with ISS. We report 188/377 patients with systemic involvement, and 13% of the total cohort had a syndromic diagnosis. The proportion of ISS patients who underwent testing was small (20%), but the pediatric patient registry uncovered a large proportion of syndromes and genetic mutations underlying their sagittal synostosis diagnosis. Even though ISS is the most common form of CS, physicians and scientists have not yet identified a genetic cause for most forms of ISS. On the other hand, syndromic forms of CS---though less common---are known to be caused by \>60 associated genetic mutations.^[@R56]^ Since genetic testing has resulted in the discovery of novel mutations related to ISS etiology,^[@R10]--[@R12],[@R18],^[@R24]^,^[@R25]^,^[@R34]^,^[@R57]^^ we suspect that increased genetic testing of these patients may result in better knowledge regarding the etiology of ISS.

CONCLUSIONS
===========

We suggest that our finding that almost half of patients with ISS have some sort of systemic involvement warrants that children diagnosed with ISS undergo complete pediatric and evaluations with appropriate utilization of molecular cytogenetics of array-CGH as well as molecular testing for pathogenic variants in the genes by single gene, gene panel, or whole exome sequencing. A statistically significant higher incidence of systemic involvement was found in the late onset ISS subgroup, which supports long-term monitoring of patients with early and late onset ISS. Many children with ISS are followed by a primary care pediatrician. Craniofacial surgeons, and other providers, should be aware that a significant proportion of patients with ISS may have syndromic or systemic involvement. Such knowledge may result in better treatment strategies for these children.
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